Boston Scientific Corporation
HealthcareNYSE:BSX · New York Stock Exchange
-$0.23 today
Vol 9.43M · Avg 18.98M
Growth Analysis
Test whether growth is durable
Review the core growth drivers, cash generation, analyst targets, and peer comparisons before deciding whether expectations still leave room for upside.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | +1.0% | +1.3% |
Equity | +4.5% | +18.7% | +22.8% | +8.0% |
Cash | N/A | N/A | +15.5% | -45.7% |
ROIC | 4.9% | 5.2% | 5.0% | 6.6% |
Analysis
Latest growth is strongest in Equity at +8.0% and weakest in Cash at -45.7%. Three-year average ROIC is 5.0%, which helps show whether that growth is being earned efficiently.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +1.0% | +9.8% (15yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | -7.4% | +12.4% (15yr)12 analysts |
Analysis
Recent growth has been strongest in Revenue at +1.0% over three years. Forward estimates point to EBIT at +12.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Wall Street Price Targets
1-year price history with analyst consensus target
Current
$46.95
Low Target
$55.00
Avg Target
$82.90
High Target
$120.00
Upside (Avg)
+76.57%
Competitor Growth
Peer CAGR comparison & forward estimates
No competitor data available.
Is BSX growing revenue?
Revenue grew 19.9% year over year, from $16.75B to $20.07B.
Is BSX turning growth into profit?
The latest net margin is 14.4%, which shows how much revenue became net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.